HealthCare Global Enterprises Ltd. (HCG) AI Stock Analysis

• Market Cap: ₹83.77B
• Dividend Yield: N/A
• Average Volume (3M): 18.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: 17.58%
• EPS Growth: -38.20%
• Country: IN
• Employees: 6,150
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.10
• Shares Outstanding: 149,302,200
• 10 Day Avg. Volume: 16,611
• 30 Day Avg. Volume: 18,118
• PEG Ratio: -21.26
• Price to Book (P/B): 7.99
• Price to Sales (P/S): 3.31
• P/FCF Ratio: 68.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹728.00
• Price Target Upside: 11.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 3.27
• Revenue Forecast (FY): ₹25.50B

• Rating: 67 Neutral
• Price Target: ₹610.00 ▼(-6.93% Downside)
• Action: Reiterated Date: 10/23/25
• Date: Action: Reiterated 10/23/25

HealthCare Global Enterprises Ltd. benefits from strong technical momentum and solid financial performance, but its high P/E ratio suggests overvaluation. The lack of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Sustained revenue growth

HCG’s consistent top-line expansion (17%+ YoY) reflects rising patient volumes and deeper penetration of oncology services across its network. Durable demand for cancer care and scale in high-complexity treatments support multi-month revenue visibility and capacity-driven growth prospects.

High gross and improving margins

Elevated gross margins and near-20% EBITDA indicate structural profitability in core oncology services and diagnostics. Margins benefit from specialized procedures and scale economics at centers, which can sustain operating leverage as volumes grow and efficiency initiatives continue over the medium term.

Strong operating cash generation

Robust operating cash flows and positive free cash flow growth show the business converting revenue into cash reliably. This enhances capacity to fund capex for radiotherapy equipment, service expansion or deleveraging, underpinning financial resilience across the next several quarters.

Negative Factors

High financial leverage

A near-2.0 debt/equity ratio signals substantial leverage for a hospital network with capital-intensive radiotherapy assets. Elevated debt increases interest obligations and reduces flexibility to invest or absorb shocks, constraining strategic initiatives and balance-sheet resilience over the medium term.

Low net profitability

Despite revenue gains, a low 2% net margin and falling net income point to cost pressures, reimbursement limits or one-off items eroding retained earnings. Persistent thin net margins limit internal funding for growth and make returns sensitive to input cost or pricing shifts over several months.

Earnings per share contraction

A sharp EPS decline suggests either elevated expenses, nonrecurring charges or dilution that materially weakens shareholder returns. Sustained EPS volatility undermines ROE and investor capacity for equity-funded expansion, signaling structural profitability and capital-allocation challenges ahead.

HealthCare Global Enterprises Ltd. Business Overview & Revenue Model

Company Description

HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, as well as reproductive medicine services, including assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates four multi-specialty hospitals, including three under the HCG brand in Ahmedabad, Bhavnagar, and Rajkot in the state of Gujarat, as well as one under operations and management contract in Hubli in the state of Karnataka that primarily provide cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, and pulmonary and critical care. In addition, the company offers medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector. As of March 31, 2021, it operated 23 cancer centers, including 1 center of excellence in Bengaluru, 2 freestanding diagnostic centers, and 1 day care chemotherapy center across India, as well as 1 cancer center in Africa. The company was founded in 1989 and is based in Bengaluru, India.

How the Company Makes Money

HCG generates revenue primarily through its healthcare services, including inpatient and outpatient treatments, surgeries, and specialized oncology services. Key revenue streams include payments from patients for treatments, consultations, and diagnostic services, as well as reimbursement from insurance companies and government health programs. Additionally, the company may earn income from partnerships with pharmaceutical firms for clinical trials and drug development, as well as from its research initiatives. HCG's strategic collaborations with healthcare providers and institutions further enhance its capabilities and market reach, contributing to its overall earnings.

HealthCare Global Enterprises Ltd. Financial Statement Overview

Summary

HealthCare Global Enterprises Ltd. shows strong revenue growth and improving profitability margins. However, the decrease in net income and high leverage indicate potential operational challenges and financial risks.

Income Statement

HealthCare Global Enterprises Ltd. has shown a strong revenue growth trajectory over the years. The company improved its revenue by 17.35% from 2024 to 2025. The gross profit margin stands at 52.11% and net profit margin at 2.00% for 2025, with a noticeable improvement in profitability metrics like EBIT and EBITDA margins, which are at 7.93% and 19.06% respectively. However, the net income has decreased compared to 2024, indicating potential operational challenges.

Balance Sheet

The company shows a moderately balanced financial structure with a debt-to-equity ratio of 1.99, indicating reliance on debt. The equity ratio at 26.02% reflects a reasonable level of equity financing. Return on Equity is low at 4.81%, suggesting limited profitability for equity holders. Overall, the balance sheet indicates a stable but leveraged position.

Cash Flow

HealthCare Global Enterprises Ltd. has demonstrated consistent positive operating cash flows, showing operational efficiency. The Operating Cash Flow to Net Income ratio is robust at 7.14, indicating strong cash flow generation relative to net income. Free Cash Flow has shown a growth of 9.39% from the previous year, reflecting healthy cash management. However, the Free Cash Flow to Net Income ratio at 2.44 highlights potential concerns in cash flow efficiency.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	23.10B	22.23B	19.12B	16.94B	13.98B	10.13B
Gross Profit	12.16B	11.91B	10.48B	9.20B	7.52B	5.27B
EBITDA	3.47B	3.13B	2.67B	2.37B	1.78B	656.22M
Net Income	370.80M	444.10M	481.55M	293.49M	537.33M	-1.93B
Balance Sheet
Total Assets	0.00	35.43B	27.07B	23.16B	22.20B	20.36B
Cash, Cash Equivalents and Short-Term Investments	3.48B	3.53B	3.03B	1.97B	2.04B	1.66B
Total Debt	0.00	18.37B	12.74B	9.01B	9.15B	9.78B
Total Liabilities	-9.90B	25.53B	18.42B	14.47B	13.36B	13.22B
Stockholders Equity	9.90B	9.22B	8.26B	8.61B	8.70B	6.97B
Cash Flow
Free Cash Flow	0.00	1.08B	988.99M	1.18B	1.49B	850.97M
Operating Cash Flow	0.00	3.17B	2.85B	2.52B	2.20B	1.21B
Investing Cash Flow	0.00	-4.88B	-2.26B	-1.33B	1.25B	-1.71B
Financing Cash Flow	0.00	-424.40M	-640.16M	-1.40B	-1.55B	1.12B

HealthCare Global Enterprises Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 655.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HCG, the sentiment is Negative. The current price of 655.45 is above the 20-day moving average (MA) of 575.17, above the 50-day MA of 607.99, and above the 200-day MA of 634.84, indicating a bearish trend. The MACD of -14.92 indicates Positive momentum. The RSI at 40.97 is Neutral, neither overbought nor oversold. The STOCH value of 32.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:HCG.

HealthCare Global Enterprises Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NH	71 Outperform	₹359.08B	75.82	―	0.24%	14.72%	8.37%
HCG	67 Neutral	₹83.77B	-247.47	―	―	17.58%	-38.20%
MAXHEALTH	66 Neutral	₹1.01T	84.46	―	0.14%	32.17%	28.12%
MEDANTA	65 Neutral	₹292.79B	83.79	―	0.04%	15.78%	15.01%
ASTERDM	62 Neutral	₹340.92B	151.95	―	0.84%	-36.14%	-93.99%
FORTIS	61 Neutral	₹663.42B	86.12	―	0.11%	15.33%	54.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

HealthCare Global Enterprises Ltd. Corporate Events

HealthCare Global Clears Rights Issue Offer to Raise Up to ₹424.7 Crore

HealthCare Global Enterprises Ltd. has finalized and filed its Letter of Offer for a rights issue of up to 8,294,566 fully paid equity shares, each with a face value of ₹10 priced at ₹512 including premium, to raise up to ₹42,468.18 lakh. The rights issue, cleared in principle by the National Stock Exchange and approved by the company’s board on February 24, 2026, will open on March 11 and close on March 25, 2026, providing existing shareholders an opportunity to participate in the company’s capital-raising plans and potentially strengthening its balance sheet for future growth in oncology services.

HCG Posts Double-Digit Revenue and EBITDA Growth in Q3 FY26 on Oncology Network Strength

HealthCare Global Enterprises Ltd. reported its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025, showing sustained growth in revenue and profitability. Consolidated revenue from operations rose 13% year-on-year in Q3 FY26 to ₹6,331 million and 16% for the nine-month period to ₹18,931 million, while adjusted EBITDA increased 20% year-on-year in both the quarter and nine months, with margins improving to 17.5% in Q3 and 18.3% for the nine months, driven by operating leverage and stable performance across regional clusters. Management highlighted that the research-led, technology-driven oncology model and focus on high-quality cancer care across medical, radiation and surgical modalities underpin the scalability of the business and support its ongoing expansion across India, positioning HCG at the forefront of specialized oncology care and reinforcing resilient demand even in a seasonally softer quarter.

HealthCare Global Board Clears Q3 and 9-Month FY26 Unaudited Results, Releases Investor Presentation

HealthCare Global Enterprises Ltd. announced that its Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and has released an accompanying investor presentation. The disclosure, made to both the National Stock Exchange of India and BSE, underscores the company’s ongoing regulatory compliance and provides investors and other stakeholders with updated financial performance information for the fiscal year to date.